THIS IS BIG!

Do you know that you can control your own formulary to reduce sky rocketing GLP-1 prices?

GLP-1s are drugs such as Ozempic/Mounjaro (same manufacturer different dosages), Wegovy/Zepbound (same manufacturer different dosages).
Employer spending on GLP-1s has increased from 7% in 2022 to 9% in 2023 (of total employer Rx spend).
Over that same timeframe, employer Rx spend increased from 21% to 27% of total healthcare spend. Prescriptions are more than 25% of an employer’s total healthcare spend.

12% of adults have Diabetes and 42% of adults in the US are obese.
KICKER: Of the 42% obese adults, only 1.7% of plan members (employees) are on a GLP-1 today. TAKEAWAY: “we’re only getting started” meaning, there are a lot of costs just waiting to hit employer benefits’ plans. Potentially a 68% increase in employer spend in the GLP-1 category!
82% of the current utilizers are female and stay on the drug(s) for approximately one year due to side effects, not losing weight, etc. Reminder: GLP-1s are appetite suppressors, diet and exercise are still required.
GLP-1s are two of the top four drugs employers spend the most on. After rebates the per employee per year cost is roughly $9-10k.
KICKER: What if male utilization of GLP-1s increases?!

Control your formulary informed by data, down to the prescribing provider and patient level.
Have control over the Prior Authorization process, a vital tool in conjunction with protocols such as a required A1-C or BMI threshold, Step Therapy, etc.
Have complete transparency into the rebate process along with drug inflation and specific knowledge of all the drug manufacturers tricks.
You can no longer afford to simply punt this critical (escalating/out of control) area of costs to a broker that benefits in increasing commissions (% of rebates or the new term ‘consulting fees’) as your costs increase.